Abstract Library

#2935 Prior Surgical Resection and Ga-68-DOTANOC PET/CT Imaging-Based Parameters: Do These Impact Outcomes in Grade II Gastroentero-Pancreatic Neuroendocrine Tumors (GEP-NETs)

Introduction: Grade 2 GEP-NETs have inherent tumor heterogeneity seen with positive expression of somatostatin (SSTR) and glucose (GLUT) receptors. Prior surgical resection and imaging parameters on Ga-68 DOTANOC PET/C are well-established variable impacting prognosis in well-differentiated grade 1 NETs. Since the degree of differentiation is variable in Grade 2 NETs, these parameters have not been studied.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Puranik A

Authors: Puranik A, Agrawal A, Rangarajan V, Shrikhande S, Dev I,

Keywords: Grade 2, GEP-NET, DOTANOC, surgical resection,

#2777 Tumor-to-Liver Ratio of Ga-68-DOTATOC PET/CT as a Prognostic Parameter in Metastatic, Well-Differentiated Gastroenteropancreatic-Neuroendocrine Tumor Patients Who Received Lanreotide Therapy

Introduction: Lanreotide is a long-acting somatostatin analogue with proven antitumor effect against metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors (GEP-NETs). Ga-68-DOTATOC PET/CT is a sensitive imaging technique for NETs by targeting somatostatin receptors.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Kim Y, Yoo C, Ryoo B, Ryu J,

Keywords: neuroendocrine tumor, lanreotide, somatostatin receptor, DOTATOC, positron emission tomography, prognosis,

#1570 Peptide Receptor Radionuclide Therapy Prolongs Survival in Neuroendocrine Neoplasms: A Single Centre Study in 1048 Patients over 10 Years

Introduction: Peptide receptor radionuclide therapy (PRRT) of somatostatin receptor (SSTR) expressing neuroendocrine neoplasms (NEN) has shown promising results about progression free survival (PFS) and overall survival (OS) in numerous phase II trials, and also in a recently published randomized controlled prospective phase III study (NETTER-1).

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Kulkarni H

Authors: Baum R, Kulkarni H, Niepsch K, Kaemmerer D, Hommann M,

Keywords: PRRT, Survival, PET/CT,

#1230 Ga-68 Somatostatin Receptor PET/CT in the Detection of Insulinoma

Introduction: Presence of somatostatin receptors on beta cells of pancreas is a matter of debate.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Prasad V

Authors: Prasad V, Blankenstein O, Plöckinger U, Pape U, Pascher A,

Keywords: somatostatin receptor PET/CT, Insulinoma,

#1226 Follow Up of ≤ 2 cm Non Functioning Pancreatic NETs in Patients with MEN1 Treated with Conservative Approach

Introduction: There is a current trend for conservative treatment of non functioning pancreatic NET (NF-PNETs), ≤ 2 cm, in patients with MEN1, which are reported to be associated with low risk of metastasis and death.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Davi' M

Authors: Davì M, Cosaro E, Malpaga A, Butturini G, Ortolani S,

Keywords: Pancreatic neuroendocrine tumor, MEN1,